Amarin taps suppliers for 'aggressive' launch

Amarin is getting all its manufacturing ducks in a row as it prepares for the debut of its new heart drug, AMR101. With positive data from two late-stage studies to support its approval app, Amarin ($AMRN) has forged new supply agreements to support an "aggressive" marketing campaign for the omega 3 drug, which is set to rival GlaxoSmithKline's Lovaza for market share. Report

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.